News & Updates

Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
06 Apr 2022

Treatment with a guideline-based thromboprophylaxis in multiple myeloma patients and the addition of pharmacy oversight to risk assessment can help reduce the risk of venous thromboembolism (VTE), suggests a recent study.

Prophylactic anticoagulants, pharmacy oversight lower VTE risk in multiple myeloma
06 Apr 2022
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
06 Apr 2022

Patients with relapsed/refractory multiple myeloma (RRMM) are at greater risk of adverse events (AEs), have low overall survival (OS), and suffer a substantial economic burden, reports a study, which suggests the need for effective treatment options.

Relapsed/refractory multiple myeloma patients burdened with poor survival, high costs
06 Apr 2022
Continued anti-VEGF use after disease control does not prevent nAMD recurrence
Continued anti-VEGF use after disease control does not prevent nAMD recurrence
06 Apr 2022

In patients with neovascular age-related macular degeneration (nAMD) who achieve functional and morphological disease stability, continuing treatment with antivascular endothelial growth factors (anti-VEGF) does not substantially reduce the risk of recurrence, reports a recent study.

Continued anti-VEGF use after disease control does not prevent nAMD recurrence
06 Apr 2022
Insulin pump, CGM use linked to better glucose control during pregnancy
Insulin pump, CGM use linked to better glucose control during pregnancy
06 Apr 2022